Cortagen, Cerluten and Cortexin are three different kinds of material: a synthetic tetrapeptide, an undefined cortex extract, and a registered drug. What the literature actually shows.
SLU-PP-915 vs SLU-PP-332 compared from the primary ERR-agonist literature: potency, subtype profile, and the real differentiator — oral bioavailability. RUO.
Methylene Blue and J-147 are both studied as mitochondria-targeting nootropic compounds, but their chemistry and mechanisms diverge sharply. A research-use comparison of an old synthetic dye versus an engineered curcumin descendant — with honest evidence and verified references.
KPV and larazotide are both studied in intestinal-barrier and inflammation research, but by different mechanisms. A sober, RUO comparison — including larazotide’s negative phase III result. References verified.
The name ‘TB-500’ covers two unrelated research molecules: full-length thymosin β4 (43 aa) and short Tβ4-derived fragments. What each one actually is, what the literature reports, and how to tell them apart. Research use only.
CJC-1295 DAC and CJC-1295 no-DAC (Modified GRF 1-29) share one peptide backbone but differ in half-life. A research-use-only comparison of structure, pharmacokinetics and the published evidence, with verified references.
BPC-157 arginate vs standard BPC-157, compared for research: the salt-form (arginine vs acetate) chemistry, what it changes for solubility and handling stability, and what it does not change about the peptide itself. Research use only.
They differ by one letter and a world of pharmacology. One is a comparatively selective alpha-MSH analogue licensed as an orphan medicine; the other is an unapproved, broad melanocortin agonist with a documented harm profile. Why the confusion persists, and what the evidence actually says.
Two peptides from one scaffold took opposite paths — one to a regulatory approval, the other to the grey market. A precise, evidence-honest comparison of receptor emphasis, regulatory standing, and documented harms for the research bench.
Three peptides chase the same idea — stabilise growth-hormone-releasing hormone so it drives pulsatile GH at the pituitary. They are not three equal options. Sorted by evidence and regulatory status, the hierarchy is steep and worth understanding before equating them.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
